Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $12.2308.

Several analysts have issued reports on CMPX shares. Compass Point set a $10.00 target price on Compass Therapeutics in a research note on Monday, October 6th. JMP Securities set a $10.00 price objective on Compass Therapeutics in a research note on Wednesday, December 3rd. William Blair assumed coverage on shares of Compass Therapeutics in a research report on Monday. They set an “outperform” rating for the company. Citigroup started coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. Finally, Raymond James Financial restated an “outperform” rating and set a $9.00 price target on shares of Compass Therapeutics in a research note on Tuesday.

Compass Therapeutics Stock Down 5.1%

Compass Therapeutics stock opened at $5.17 on Friday. The firm has a 50 day moving average price of $4.98 and a 200-day moving average price of $3.90. Compass Therapeutics has a twelve month low of $1.33 and a twelve month high of $5.86. The company has a market capitalization of $919.54 million, a P/E ratio of -11.49 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Equities analysts expect that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

A number of large investors have recently made changes to their positions in CMPX. Russell Investments Group Ltd. raised its stake in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. Apollon Wealth Management LLC purchased a new position in Compass Therapeutics during the 3rd quarter valued at about $35,000. CIBC Bancorp USA Inc. bought a new stake in shares of Compass Therapeutics during the third quarter valued at about $37,000. Creative Planning purchased a new stake in shares of Compass Therapeutics in the second quarter worth about $30,000. Finally, Victory Capital Management Inc. boosted its position in shares of Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after acquiring an additional 2,164 shares during the period. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.